Oxytocin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Cadence is once daily, every day, by subcutaneous injection, held for 8 to 12 weeks and extended to 16 weeks where desired. There is no loading phase and no rest week inside the block; only the dose moves, stepping up every two weeks until it settles at 500 mcg from week 9 onward. At 10 mg/mL every step on the ladder falls between 1 and 5 units, so a syringe marked to 30 or 50 units reads those volumes far more accurately than a full 100 unit barrel, which is the same point the master sheet makes for administrations of 10 units (0.10 mL) or smaller. Sites rotate across abdomen, thighs, and upper arms, with the needle entering subcutaneous tissue at 45 to 90 degrees, no aspiration, a slow push, and a 5 to 10 second pause before withdrawal. One point deserves stating plainly: the route in this protocol is subcutaneous, not intranasal. Much of the human literature the master sheet cites used intranasal oxytocin, and the master notes that oxytocin does not significantly cross the blood-brain barrier from the bloodstream, so a peripheral injection primarily targets peripheral OXTR while intranasal administration is thought to better engage central receptors.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: the ladder opens at 100 mcg daily, 1 unit per injection at 10 mg/mL.
• Weeks 3 to 8: stepwise increases through 200, 300, and 400 mcg daily, moving up every two weeks.
• Weeks 9 to 12: the top of the ladder at 500 mcg daily, 5 units per injection, held to the end of the block or through week 16 if extended.
• Acute against chronic: the master records a single intranasal dose reducing caloric intake and increasing fat oxidation, while modest weight loss, improved insulin sensitivity, and reduced visceral fat are reported only from chronic treatment across weeks.
• An 8 week trial using 96 IU per day intranasally reported no serious adverse events.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe: 100 mcg = 1 unit, 200 mcg = 2 units, 300 mcg = 3 units, 400 mcg = 4 units, 500 mcg = 5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store frozen at minus 20 °C for long term storage, or refrigerate at 2 to 8 °C for shorter periods; protect from light and moisture.
• Reconstituted: refrigerate at 2 to 8 °C; stable for up to 28 to 30 days with bacteriostatic water. Mark the date and discard after 4 weeks.

• Extended storage: aliquot reconstituted solution into sterile vials and freeze at minus 20 °C. Do not subject the solution to repeated freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake. A 10 mg vial at 10 mg/mL holds 1.0 mL, about 100 units, so a 500 mcg daily dose empties one vial in 20 days, comfortably inside the 28 to 30 day discard window.

Supplies Needed

Planning is based on the master sheet's 8 to 16 week daily protocol with gradual titration, which uses 0.7 mg in the first week at 100 mcg daily and peaks at 3.5 mg per week once the 500 mcg daily step is reached.

Peptide Vials (Oxytocin, 10 mg vial):

• Eight weeks of the titration totals 14 mg, twelve weeks totals 28 mg, and sixteen weeks totals 42 mg; the master sheet plans about 3 vials for 8 weeks, about 5 vials for 12 weeks, and about 6 vials for 16 weeks, because the 28 to 30 day discard window retires a partly used vial before the low dose weeks can finish it.

Insulin Syringes (U-100):

• Per week: 7 syringes, one per day (U-100, with 30 unit or 50 unit markings preferred, since every dose on this ladder falls between 1 and 5 units).
• 8 weeks: 56 syringes. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle of bacteriostatic water covers 10 vials, more than the 6 vials a full 16 week run calls for.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, which is 14 per week on the once daily schedule.
• 8 weeks: 112 swabs, so two 100 count boxes. 12 weeks: 168. 16 weeks: 224, so three 100 count boxes.

Important Notes

Practical considerations for consistency and safety.

• Route matters for reading the evidence. This protocol is subcutaneous, while much of the human research the master sheet cites is intranasal. Oxytocin does not significantly cross the blood-brain barrier from the bloodstream, so subcutaneous dosing primarily engages peripheral OXTR, and intranasal administration is thought to better engage central receptors. The subcutaneous evidence the master does cite is peripheral: a randomized trial in which a 4 mcg subcutaneous injection reduced heat pain intensity and unpleasantness on the treated arm.
• Titration is the design, not a formality. The ladder climbs from 100 mcg to 500 mcg daily in five steps across 8 to 12 weeks rather than starting at the top, and the master sheet treats 500 mcg as the ceiling of the daily range.
• Use a new sterile insulin syringe for every injection and dispose of it in a sharps container. At 10 mg/mL a full dose is 1 to 5 units, so a 30 unit or 50 unit barrel reads the volume far more reliably than a 100 unit barrel.
• Rotate injection sites across abdomen, thighs, and upper arms to reduce local irritation and lipohypertrophy. Inject slowly and wait a few seconds before withdrawing the needle.
• Use aseptic technique when withdrawing doses, discard reconstituted solution that becomes cloudy or discolored or shows particles, and log the daily dose and site rotation to keep the block consistent.
• Regulatory Note: oxytocin is an established approved uterotonic, used clinically to induce labor and to reduce postpartum bleeding, but at doses far larger than the research amounts described here, and the research applications in this protocol are not approved indications. The master sheet records a placebo-like safety profile at doses roughly equivalent to 18 to 40 IU intranasally per administration, about 30 to 67 mcg, and an 8 week trial at 96 IU per day intranasally with no serious adverse events. The master sheet does not record a WADA classification for this compound. Supplied for research purposes only, not for human consumption.

How This Works

Oxytocin acts by binding oxytocin receptors (OXTR), G-protein coupled receptors expressed widely in both central and peripheral tissues. In the brain it works as a neuromodulator: it is produced in the hypothalamus and released from the posterior pituitary, and it is also released directly within brain regions involved in emotion and social behavior. Activation of central OXTR influences neurotransmitter systems, enhancing prosocial signaling through dopamine and damping the stress response through the hypothalamic-pituitary-adrenal axis, and those actions underlie the observed effects on trust, empathy, and social bonding. Peripherally, oxytocin contracts smooth muscle, including uterine contraction during labor and milk ejection in lactation, and it can also modulate pain perception and inflammation, with studies showing that subcutaneous oxytocin produces local analgesia. The route limitation is central to interpreting this protocol: oxytocin does not significantly cross the blood-brain barrier from the bloodstream, so peripheral administration primarily targets peripheral OXTR, while intranasal administration is thought to better engage central receptors.

Benefits & Side Effects

Observations from the published record.

• Social and behavioral: oxytocin is associated with increased trust, social bonding, and reduced anxiety in social situations, and early studies show intranasal oxytocin can modestly improve social cognition or reduce anxiety in some populations.
• Psychiatric and neurological: it is being explored in PTSD, depression, and addiction, where its role in reducing the stress response and fear makes it a candidate for adjunctive treatment.
• Metabolic and weight management: a single intranasal dose has been shown to reduce caloric intake and increase fat oxidation, while animal studies and small trials suggest chronic oxytocin treatment can produce modest weight loss, improved insulin sensitivity, and reduced visceral fat.
• Analgesic and anti-inflammatory: a randomized trial found that a subcutaneous injection of oxytocin at 4 mcg significantly reduced ratings of heat pain intensity and unpleasantness on the treated arm.
• Reproductive health: as an established uterotonic, oxytocin is routinely used to induce labor or reduce postpartum bleeding, at doses much larger than those used in research protocols.
• Safety and side effects: the master sheet describes a placebo-like safety profile at doses roughly equivalent to 18 to 40 IU intranasally per administration, about 30 to 67 mcg, and an 8 week trial at 96 IU per day intranasally reported no serious adverse events. Because oxytocin contracts smooth muscle, including uterine muscle, the uterotonic action is a property of the compound rather than an incidental one. Mild injection-site irritation and lipohypertrophy are the practical local considerations on a daily subcutaneous schedule.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair the protocol with a balanced, nutrient-dense diet tailored to energy needs and research goals.
• Keep regular physical activity in place, combining resistance training and aerobic exercise to support overall metabolic health.
• Prioritize sleep of 7 to 9 hours and active stress management, both of which support the neuroendocrine systems this compound acts on.
• Hold injection timing and site rotation steady day to day, which supports consistent absorption and keeps local reactions to a minimum.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Intranasal Oxytocin for Obesity: 8-week trial using 96 IU per day in adults (PubMed).
2. Subcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized-Controlled Trial (PubMed).
3. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research (PubMed).
4. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass (Aging Journal).